Glioma surveillance imaging—An interview with Dr Sotirios Bisdas

Glioma surveillance imaging—An interview with Dr Sotirios Bisdas

The Power of Imaging in Neuro-Oncology

“The multimodality and combined MRI/PET imaging is expected to provide the necessary framework for personalised treatment regimes, and I’ll put special emphasis here on immunotherapy, and ultimately guidance towards precision oncology…glioma patients will benefit particularly from this approach.”

— Dr Sotirios Bisdas

Dr Sotirios Bisdas, IAG’s Head of Neuro-Oncology and Neurology Clinical Research speaks in the podcast on glioma surveillance imaging. He talks about his recently published paper ‘Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook’ , the various modalities and techniques such as MR perfusion, diffusion, spectroscopy, molecular imaging, as well as multimodality imaging and how he sees the field of clinical research is changing.

Full podcast: here

Full paper: here


Dr Sotirios Bisdas, Consultant Neuroradiologist and MRI and Clinical Lead at the National Hospital for Neurology in London, Associate Professor in Neuroradiology at the Institute of Neurology, University College London, and Professor of Radiology and Neuroradiology at the University of Tübingen, Germany. He is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions. He co-authored 130 peer-reviewed publications, 7 book chapters related to advanced MRI in neurological and oncological diseases. He is actively involved in designing and publishing guidelines for the use of perfusion imaging in Oncology.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:

Reach out:

Follow the Company: Linkedin